RECOVER trial: VNS shows durable benefit in resistant depression
The RECOVER trial, a 12-month triple-blind randomized study in 493 adults with markedly treatment-resistant major depressive disorder, compared adjunctive active versus sham vagus nerve stimulation (VNS). The prespecified primary outcome did not differ between groups, but the trial reported that secondary measures of symptoms, function, and quality of life significantly favored active stimulation, and over 80% of participants who benefited at 12 months retained gains at 18 and 24 months.
Most relevant for: Adults with markedly treatment-resistant major depressive disorder, defined in the trial as having failed at least four antidepressant treatments in the current episode.
Read the original at The American Journal of PsychiatrySummary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.
Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.
Specialties
More psychiatry updates
- Caring Letters Not Linked to Lower Suicide Mortality in VeteransOct 14, 2026
- US benzodiazepine dispensing fell 26.7% from 2013 to 2024Sep 30, 2026
- Class II recall: Safecor Health, LLC: Fluphenazine HCl Elixir, USP, 5 mg per 1 mL, Delivers: 10 mL, Oral Elixir, PAI, Sep 23, 2026
- Class II recall: Safecor Health, LLC: Fluphenazine HCl Elixir, USP, 5 mg per 10 mL, Delivers: 10 mL, Oral Elixir, PAI,Sep 23, 2026
- Class II recall: Safecor Health, LLC: Fluphenazine HCl Elixir, USP, 10 mg per 2 mL, Delivers: 10 mL, Oral Elixir, PAI,Sep 23, 2026